Gene News and Research

Latest Gene News and Research

SurModics, EGEN continue collaboration on long-term controlled release of siRNA complexes

SurModics, Inc., a leading provider of drug delivery and surface modification technologies to the healthcare industry and EGEN, Inc., a privately held biopharmaceutical company focused on developing nucleic acid (DNA and RNAi) therapeutics for the treatment of human diseases, are pleased to announce they have executed a continuation of their feasibility collaboration focused on long-term controlled release of siRNA complexes.

28 Jul 2010

Research findings provide new insight into skeletal development

Too little of a protein called neogenin results in a smaller skeleton during development and sets the stage for a more fragile bone framework lifelong, Medical College of Georgia researchers report.

28 Jul 2010

Scientists identify genetic variants for breast cancer

Women with higher risk scores that consisted of having certain genetic variants most strongly linked to breast cancer had an associated higher risk of breast cancer, with these scores also highly predictive of estrogen receptor-positive disease, according to a study in the July 28 issue of JAMA.

28 Jul 2010

CvergenX acquires global rights to InterveneXRT technology for individualization of radiation therapy

Moffitt Cancer Center and CvergenX, Inc., announced today that they have entered into a licensing agreement under which CvergenX has acquired the exclusive worldwide rights to a technology platform that individualizes radiation therapy, InterveneXRT™. Researchers at Moffitt have used gene expression analysis and systems biology to create a radio-sensitivity classification index for individual tumors.

28 Jul 2010

Affymetrix to develop, commercialize Axiom Chinese myDesign Genotyping Array

Affymetrix, Inc. today announced that it will develop and commercialize the Axiom Chinese myDesign Genotyping Array, the first product that provides maximum power for genome-wide association studies specifically on Chinese populations.

28 Jul 2010

New study reveals potential role of TGF-β1 in kidney disease

Fibrosis in the kidney is one of the key causes of progressive renal failure. High levels of the inflammatory molecule TGF-β1 in the kidney tubules due to tissue damage can cause fibrosis as well as nephron degeneration, resulting in loss of kidney function. To clarify the mechanisms regulating TGF-β1-mediated renal fibrosis, Koesters et al expressed high levels of TGF-β1 in renal tubules of mice. Nephron degeneration in this system was mediated by decomposition of the tubular cells. These data suggest that TGF-β1 may play a novel role in cell death of renal cells, thus contributing to renal fibrosis.

28 Jul 2010

Scientists develop laser activated carbon nanoparticles for drug, gene delivery

Using chemical "nanoblasts" that punch tiny holes in the protective membranes of cells, researchers have demonstrated a new technique for getting therapeutic small molecules, proteins and DNA directly into living cells.Carbon nanoparticles activated by bursts of laser light trigger the tiny blasts, which open holes in cell membranes just long enough to admit therapeutic agents contained in the surrounding fluid. By adjusting laser exposure, the researchers administered a small-molecule marker compound to 90 percent of targeted cells - while keeping more than 90 percent of the cells alive.

28 Jul 2010

Dopamine-releasing cells essential for detected odor to be associated with negative experience: Study

It is common sense that it's worth learning what things and situations are harmful to us if we want to have a long and healthy life. For example, after getting a nasty sunburn, we learn our lesson, and apply sun cream before going sunbathing next time. The importance of such learned avoidance strategies is reflected by the fact that even fruit flies possess them.

27 Jul 2010

Scientists discover mechanism behind flushing reaction caused by nicotinic acid treatment

Cholesterol influences the health of our hearts and blood vessels. Conventional treatment attempts to reduce the level of "bad" cholesterol, LDL cholesterol, in the blood plasma. The opposite approach, which involves increasing the concentration of "good" HDL cholesterol using nicotinic acid, has proven unpopular among patients up to now. The reason for this is that treatment with nicotinic acid has an unpleasant but harmless side-effect: the drug makes patients turn quite red in the face. Scientists at the Max Planck Institute for Heart and Lung Research in Bad Nauheim have now discovered the mechanism behind this effect, which is known as flushing. This will enable the development of flush inhibitors and thereby the more effective prevention of cardiovascular diseases.

27 Jul 2010

Circle Biologics introduces single device Autologous Platelet Concentrator Platform

Circle Biologics, Inc. has announced a technological break-through in regenerative medicine – its Autologous Platelet Concentrator Platform. This innovative single device platform is the first of its kind to incorporate both autologous cell concentration and protein concentration in one point-of-care device.

27 Jul 2010

PIK3CA, KRAS mutations in tumor can predict patients’ response to treatment: Research

Drugs such as everolimus that target the protein mTOR are used to treat several forms of cancer, but not all patients respond to the treatment. A team of researchers, led by Alberto Bardelli, at the University of Turin Medical School, Italy, has now identified a way to help predict which patients will respond to such drugs.

27 Jul 2010

Clontech Laboratories, TET Systems expand license agreement

Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., and TET Systems (TET), a privately-held German biotech company based in Heidelberg, today announced that they have signed an amendment to their existing license agreement. Under the expanded license agreement, Clontech obtains rights to develop, manufacture and commercialize novel Tet Systems products as the Tet-On® 3G™ Inducible Expression System.

26 Jul 2010

Axela acquires Xceed Molecular

Axela Inc., an innovator in systems that multiplex protein biomarker testing in clinical research and diagnostics, has acquired Xceed Molecular, developer of the award-winning Ziplex® System for gene-expression analysis, the Breast Cancer Prognostic Assay, and Colon Cancer Xpress chip. The new Axela will be introduced at the 2010 American Association of Clinical Chemistry (AACC) annual meeting and Clinical Lab Expo, which takes place July 25 – 29 at the Anaheim Convention Center in California.

26 Jul 2010

Asuragen reports collaborative study results of advanced PCR-based molecular profiling of FMR1 gene

Asuragen, Inc. announced today the results from two collaborative studies, one with the University of California Davis M.I.N.D. Institute and another with Rush University Medical Center, that demonstrate comprehensive molecular profiling of the Fragile X Mental Retardation (FMR1) gene using advanced PCR-based methods.

26 Jul 2010

HTG patients face increased risk for heart disease, stroke: Study

It can make blood look like cream of tomato soup. Patients with high levels of triglycerides in their blood, a disease called hypertriglyceridemia face an increased risk for heart disease and stroke. HTG affects one in 20 people in North America and is also associated with obesity, diabetes and pancreatitis. Most people now understand the importance of LDL, the bad cholesterol and HDL, the good cholesterol, to their overall health.

26 Jul 2010

Control of cell migration gene can reduce spread of oral cancer cells: Study

The spread of cancer cells in the tongue may be reduced if a gene that regulates cancer cell migration can be controlled, according to new research at the University of Illinois at Chicago.

26 Jul 2010

Prevalence of HD substantially underestimated in the UK

The prevalence of Huntington's disease is substantially underestimated in the UK, with significant implications for those affected, the healthcare system, and research. New estimates of prevalence, and their implications, are discussed in a comment published in an upcoming Lancet, written by Professor Sir Michael Rawlins, who is the Chairman of the UK National Institute for Health and Clinical Excellence, but writes in his capacity as an Honorary Professor of the London School of Hygiene and Tropical Medicine, UK.

23 Jul 2010

NYC hospitals agree to pilot program to cut medical-malpractice costs

To cut medical-malpractice costs, five New York City hospitals have agreed to a pilot program to divulge medical mistakes early, offer settlements quickly and use special state 'health courts,' where judges will help negotiate agreements before cases go to trial. The program, funded for three years with $3 million from the federal government, aims to cut the $1.4 billion spent annually in New York State on medical-malpractice premiums, hospital and state officials say.

23 Jul 2010

GRB7 gene drives an aggressive form of breast cancer, researchers find

Oregon Health & Science University Knight Cancer Institute researchers found that the GRB7 gene drives an aggressive form of breast cancer and acts independently of the HER-2 gene, known to be a stimulator of breast cancer growth. Isolating the role of this gene could ultimately help fine-tune a patient's treatment and enable physicians to provide a more accurate prognosis.

23 Jul 2010

Research on new treatments for FXS to be presented at International Fragile X Conference

Accelerated research findings leading to potentially significant new treatments for fragile X syndrome will be presented to nearly 1,000 family members and professionals at the 12th International Fragile X Conference in Dearborn July 21-25.

23 Jul 2010

Gene News and Research

Latest Gene News and Research

SurModics, EGEN continue collaboration on long-term controlled release of siRNA complexes

Research findings provide new insight into skeletal development

Scientists identify genetic variants for breast cancer

CvergenX acquires global rights to InterveneXRT technology for individualization of radiation therapy

Affymetrix to develop, commercialize Axiom Chinese myDesign Genotyping Array

New study reveals potential role of TGF-β1 in kidney disease

Scientists develop laser activated carbon nanoparticles for drug, gene delivery

Dopamine-releasing cells essential for detected odor to be associated with negative experience: Study

Scientists discover mechanism behind flushing reaction caused by nicotinic acid treatment

Circle Biologics introduces single device Autologous Platelet Concentrator Platform

PIK3CA, KRAS mutations in tumor can predict patients’ response to treatment: Research

Clontech Laboratories, TET Systems expand license agreement

Axela acquires Xceed Molecular

Asuragen reports collaborative study results of advanced PCR-based molecular profiling of FMR1 gene

HTG patients face increased risk for heart disease, stroke: Study

Control of cell migration gene can reduce spread of oral cancer cells: Study

Prevalence of HD substantially underestimated in the UK

NYC hospitals agree to pilot program to cut medical-malpractice costs

GRB7 gene drives an aggressive form of breast cancer, researchers find

Research on new treatments for FXS to be presented at International Fragile X Conference

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting